ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BBNX vs JNJ // NET PROFIT MARGIN

Beta Bionics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: BBNX 2 — JNJ 8
▲ NET PROFIT MARGIN LEADER: JNJ
net-margins
28.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BBNX VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BBNX JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 55.40% 67.90% -12.50 JNJ /gross-margins <GO>
Return on Invested Capital (ROIC) -22.10% 25.50% -47.60 JNJ /roic <GO>
EV/EBITDA & P/E Valuation — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield -5.88% 2.97% -8.85 JNJ /fcf-yield <GO>
Operating Margin -60.00% 34.70% -94.70 JNJ /operating-margins <GO>
Net Profit Margin ACTIVE -60.00% 28.50% -88.50 JNJ /net-margins <GO>
Revenue Growth (YoY) 53.90% 6.00% +47.90 BBNX /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 12.82 5.59 +7.23 BBNX /balance-sheet <GO>
Piotroski F-Score Quality 4/9 8/9 -4.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 45.8 62.1 -16.30 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $955.8M $662.49B -$661.54B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BBNX REV JNJ REV BBNX GROSS % JNJ GROSS % BBNX FCF JNJ FCF
FY 2025 $100.3M $94.19B 55.4% 67.9% -$56.2M $19.70B
FY 2024 $65.1M $88.82B 55.1% 69.1% -$51.7M $19.84B
FY 2023 $12.0M $85.16B — — -$32.4M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BBNX // BETA —
JNJ // BETA 1.08